Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EDIT
Strong SellHot AirEditas Medicine, Inc. · Healthcare · United States · $485M · Avg Vol: $6M/d
COMPANY DESCRIPTION
Editas Medicine, Inc. is a clinical-stage biotechnology company dedicated to developing gene editing medicines using CRISPR technology to treat serious diseases. As a pioneer in CRISPR gene editing, it holds key intellectual property and collaborates strategically with pharmaceutical partners. The company is a leading player in a transformative area of genetic medicine, targeting unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 19.7M | 78.1M | 32.3M | 40.5M | 27.1% | 47.0M | 25.9M | 19.4M | -30.8% |
| EPS | -2.85 | -1.44 | -2.02 | -2.88 | -1.80 | — | -0.66 | -0.83 | -0.75 | — |
| Shares | — | 153.5M | 81.8M | 82.7M | 97.9M | -36.2% | — | — | — | — |
| Debt | — | 43.9M | 36.5M | 35.0M | 18.1M | -25.6% | 15.5M | — | — | — |
| Equity | — | 360.7M | 349.1M | 134.3M | 27.3M | -57.7% | — | — | — | — |
| Op CF | — | -177.3M | -132.2M | -210.3M | -165.2M | — | -119.9M | — | — | — |
| Inv CF | — | 114.1M | -3.7M | 162.1M | 138.7M | — | — | — | — | — |
| Fin CF | — | 1.3M | 118.0M | 56.0M | 40.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EDIT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EDIT | Editas Medicine, Inc.(you) | $485M | 14 | Strong Sell |
| ZURA | Zura Bio Limited | $548M | 16 | Strong Sell |
| LRMR | Larimar Therapeutics, Inc. | $417M | 16 | Strong Sell |
| AVIR | Atea Pharmaceuticals, Inc. | $430M | 17 | Strong Sell |
| ENTA | Enanta Pharmaceuticals, Inc. | $396M | 13 | Strong Sell |
| CABA | Cabaletta Bio, Inc. | $529M | 10 | Strong Sell |
| RCKT | Rocket Pharmaceuticals, Inc. | $424M | 10 | Strong Sell |
| GALT | Galectin Therapeutics Inc. | $405M | 11 | Strong Sell |
| ALT | Altimmune, Inc. | $605M | 16 | Strong Sell |
| EVMN | Evommune, Inc. | $480M | 8 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%